Modern approaches of effective prevention of NSAIDs-gastropathy
Abstract
The aim of review. To present current approach for NSAIDs-gastropathy prevention.
Summary. Upper gastrointestinal lesions, related to intake of nonsteroid anti-inflammatory drugs (NSAIDs) represent a serious social and medical problem. This is related to increase in NSAIDs and low dozes of aspirin users number, who are mostly elderly people, often having combination of several diseases with serious risk of drug-induced complications. Even after safer class of NSAIDs, i.e. selective cyclooxygenase-2 (COX-2) inhibitors were introduced to clinical practice and obvious successes in treatment of H. pylori-associated peptic ulcers, frequency of NSAIDs gastropathy still remains high. Besides that, NSAIDs gastropathy complications, such as bleeding and perforations, are accompanied by high mortality and serious treatment expenditures. This requires adequate prophylaxis of this pathology. Proton pump inhibitors (PPIs) play a special role as the main class of drugs used for NSAIDs gastropathy prevention at the present time. This review presents advantages of pantoprazole — a PPI, that possesses the minimal risk of unfavorable pharmacological interaction with drugs of other pharmacological classes.
Conclusion. Application of less aggressive NSAIDs — selective COX-2 inhibitors and H. pylori eradication reduce risk of serious complications, but does not eliminate it completely. Therefore long-term PPI application is required for prevention of NSAID-related ulcers and gastro-intestinal bleeding in patients who receive NSAIDs on regular basis, in the case if they have risk factors for NSAIDs-gastropathy.
About the Author
A. Ye. Karateyev
Federal State Budget Scientific Institution «Nasonova scientific research institute of rheumatology»
Russian Federation
Russian Federation
Karateyev Andrey Ye. — MD, PhD, head of laboratory of gastroenterology
115522, Moscow, Kashirskoe highway, 34А.
References
1. Pain (practical manual for doctors) / Ed.: N.N. Yakhno, M.L.Kukushkina. M.: Publishing house of Russian Academy of Medical Science, 2012, 512 c.
2. Karateyev A.Ye., Nasonov Ye.L., Yakhno N.N. Rational application of nonsteroid anti-inflammatory drugs (NSAID) in clinical practice: clinical guidelines. Sovremennaya revmatologiya 2015; 1:4-24.
3. Zhou Y., Boudreau D.M., Freedman A.N. Trends in the use of aspirin and nonsteroidal anti-inflammatory drugs in the general U.S. population. Pharmacoepidemiol Drug Saf 2014; 23(1):43-50.
4. Scarpignato C., Lanas A., Blandizzi C., et al. Safe prescribing of non-steroidal anti-inflammatory drugs in patients with osteoarthritis – an expert consensus addressing benefits as well as gastrointestinal and cardiovascular risks. BMC Medicine 2015; 13:55 doi:10.1186/s12916-015-0285-8
5. Harirforoosh S., Asghar W., Jamali F. Adverse effects of nonsteroidal antiinflammatory drugs: An update of gastrointestinal, cardiovascular and renal complications. J Pharm Pharm Sci (www.cspsCanada.org) 2013; 16(5):821-47.
6. Ivashkin V.T., Sheptulin A.A. Stomach and duodenal peptic ulcer in elderly and senile patients. Rus med zhurn 1999; 7(16):769-71.
7. Del Piano M., Bianco M.A., Cipolletta L., et al. The «Prometeo» study: online collection of clinical data and outcome of Italian patients with acute nonvariceal upper gastrointestinal bleeding. J Clin Gastroenterol 2013; 47(4):33-7. doi:10.1097/MCG.0b013e3182617dcc.
8. Nagasue T., Nakamura S., Kochi S., et al. Time trends of the impact of Helicobacter pylori infection and nonsteroidal anti-inflammatory drugs on peptic ulcer bleeding in Japanese patients. Digestion 2015; 91(1):37-41. doi:10.1159/000368810. Epub 2015 Jan 20.
9. Thomsen R., Riis A., Christensen S., et al. Outcome of peptic ulcer bleeding among users of traditional nonsteroidal anti-inflammatory drugs and selective cyclooxygenase-2 inhibitors. Aliment Pharmacol Ther 2006; 24(10):1431-8.
10. Thomsen R., Riis A., Munk E., et al. 30-day mortality after peptic ulcer perforation among users of newer selective COX-2 inhibitors and traditional NSAIDs: a population-based study. Am J Gastroenterol 2006; 101(12):270410.
11. Каратеев А.Е., Насонова В.А. Развитие и рецидивирование язв желудка и двенадцатиперстной кишки у больных, принимающих нестероидные противовоспалительные препараты. Тер арх 2008; 5:62-6.
12. Sostres C., Gargallo C.J., Lanas A. Interaction between Helicobacter pylori infection, nonsteroidal anti-inflammatory drugs and/or low-dose aspirin use: Old question new insights. World J Gastroenterol 2014; 20(28):9439-50 DOI: http://dx.doi.org/10.3748/wjg.v20.i28.9439
13. Huang J., Sridhar S., Hunt R. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 2002; 359:14-22.
14. Sostres C., Carrera-Lasfuentes P., Benito R., et al. Peptic ulcer bleeding risk. The role of Helicobacter pylori infection in NSAID/Low-Dose Aspirin Users. Am J Gastroenterol 2015; 110(5):684-9. doi:10.1038/ajg.2015.98. Epub 2015 Apr 21.
15. Graham D., White R., Morelend L. Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDs. Ann Inter Med 1993; 119:257-62.
16. Raskin J., White R., Jackson J. Misoprostol dosage in the prevention of nonsteroidal anti-inflammatory druginduced gastric and duodenal ulcers: a comparson of three regimens. Ann Intern Med 1995; 123:344-50.
17. Cullen D., Bardhan K., Eiser M., et al. Primary gastroduodenal prophylaxis with omeprazole for non-steroidal anti-inflammatory drug users. Aliment Pharmacol Ther 1998; 12:135-40.
18. Ekstrom P., Carling L., Wetterhus S., et al. Prevention of peptic ulcer and dyspeptic symptoms with omeprazole in patients receiving continuous non-steroidal anti-inflammatory drug therapy. A Nordic multicentre study. Scand J Gastroenterol 1996; 31:753-8.
19. Graham D., Agrawal N., Campbell D., et al. Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs. Arch Intern Med 2002; 162:169-75
20. Helin-Salmivaara A., Saarelainen S., Gronroos J., et al.
21. Risk of upper gastrointestinal events with the use of various NSAIDs: A case-control study in a general population. Scan J Gastroenterol, 2007; 42:923-32.
22. Moore A., Makinson G., Li C. Patient-level pooled analysis of adjudicated gastrointestinal outcomes in celecoxib clinical trials: meta-analysis of 51,000 patients enrolled in 52 randomized trials. Arthritis Res Ther 2013;15(1):6. doi:10.1186/ar4134.
23. Chan F., Lanas A., Scheiman J., et al. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. Lancet 2010; 376:173-79.
24. Castellsague J., Riera-Guardia N., Calingaert B., et al. Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project). Drug Saf 2012; 35(12):1127-46.
25. Silverstein F., Faich G., Goldstein J., et al. Gastrointestinal toxicity with celecoxib versus nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxid long-term arthritis safety study. JAMA 2000; 84:1247-55.
26. Chan F., Wong V., Suen B., et al. Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial. Lancet 2007; 369:1621-6.
27. Laine L., Curtis S.P., Cryer B., et al. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 2007; 369:465-73.
28. Singh G., Lanes S., Triadafilopoulos G. Risk of serious upper gastrointestinal and cardiovascular tromboembolic complications with meloxicam. Am J Med 2004; 117:100-6.
29. Scheiman J. The use of proton pump inhibitors in treating and preventing NSAID-induced mucosal damage. Arthritis Res Ther 2013; 15 (Suppl. 3):5.
30. Goldstein J.L., Cryer B. Gastrointestinal injury associated with NSAID use: a case study and review of risk factors and preventative strategies. Drug Healthc Patient Saf 2015; 7:31-41. doi:10.2147/DHPS.S71976. eCollec-tion 2015.
31. Yilmaz S., Bayan K., Dursun M., et al. Does adding misoprostol to standard intravenous proton pump inhibitor protocol improve the outcome of aspirin/NSAID-induced upper gastrointestinal bleeding?: a randomized prospective study. Dig Dis Sci 2007; 52(1):110-8. Epub 2006 Dec 7.
32. Taha A., Hudon N., Hawkey C., et al. Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs. N Engl J Med 1996; 334:1435-9.
33. Laine L., Kivitz A., Belo A., et al. Double-blind randomized trials of single-tablet ibuprofen/high-dose famotidine vs. ibuprofen alone for reduction of gastric and duodenal ulcers. Am J Gastroenterol 2012; 107:379-86.
34. Ng F., Wong S., Lam K., et al. Famotidine is inferior to pantoprazole in preventing recurrence of aspirinrelated peptic ulcers or erosions. Gastroenterology 2010; 138(1):82-8.
35. Ng F., Tunggal P., Chu W., et al. Esomeprazole compared with famotidine in the prevention of upper gastrointestinal bleeding in patients with acute coronary syndrome or myocardial infarction. Am J Gastroenterol 2012, 107(3):389-96.
36. Vergara M., Catalán M., Gisbert J.P., Calvet X. Meta-analysis: role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users. Aliment Pharmacol Ther 2005; 21(12):1411-8 [PMID:15948807 doi:10.1111/j.1365-2036.2005.02444.x]
37. Tang C.L., Ye F., Liu W., Pan X.L., Qian J., Zhang G.X. Eradication of Helicobacter pylori infection reduces the incidence of peptic ulcer disease in patients using nonsteroidal anti-inflammatory drugs: a metaanalysis. Helicobacter 2012; 17:286-296 [PMID:22759329 doi:10.1111/j.1523-5378.2012.00942.x]
38. De Leest H.T., Steen K.S., Lems W.F., et al. Eradication of Helicobacter pylori does not reduce the incidence of gastroduodenal ulcers in patients on long-term NSAID treatment: double-blind, randomized, placebo-controlled trial. Helicobacter 2007; 12(5):477-85.
39. Hawkey C., Tulassay Z., Szczepanski L., et al. Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study. Helicobacter eradication for lesion prevention. Lancet 1998; 352(9133):1016-21.
40. Chan F.K., Chung S.C., Suen B.Y., et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med 2001; 344:967-73 [PMID:11274623 doi:10.1056/NEJM200103293441304]
41. Chan F.K., Ching J.Y., Suen B.Y., et al. Effects of Helicobacter pylori infection on long-term risk of peptic ulcer bleeding in low-dose aspirin users. Gastroenterology 2013; 144(3):528-35. doi:10.1053/j.gastro.2012.12.038. Epub 2013 Jan 16.
42. Malfertheiner P., Megraud F., O’Morain C., et al. Management of Helicobacter pylori infection – the Maastricht IV/ Florence Consensus Report. Gut 2012; 61:646-64. doi:10.1136/gutjnl-2012-302084
43. Singh G., Triadafilopoulos G. Appropriate choice of proton pump inhibitor therapy in the prevention and management of NSAID-related gastrointestinal damage. Int J Clin Pract. 2005; 59(10):1210-7.
44. Regula J., Butruk E., Dekkers C.P., et al. Prevention of NSAID-associated gastrointestinal lesions: a comparison study pantoprazole versus omeprazole. Am J Gastroenterol 2006; 101(8):1747-55. Epub 2006 Jun 30.
45. Devault K. Pantoprazole: a proton pump inhibitor with oral and intravenous formulations. Expert Rev Gastroenterol Hepatol 2007; 1(2):197-205. doi: 10.1586/17474124.1.2.197.
46. Moreira Dias L. Pantoprazole: a proton pump inhibitor. Clin Drug Investig 2009; 29 (Suppl. 2):3-12. doi:10.2165/1153121-S0-000000000-00000.
47. Van Rensburg C.J., Cheer S. Pantoprazole for the treatment of peptic ulcer bleeding and prevention of rebleeding. Clin Med Insights Gastroenterol 2012; 5:51-60. doi: 10.4137/CGast.S9893. eCollection 2012.
48. Wang J., Yang K., Ma B., et al. Intravenous pantoprazole as an adjuvant therapy following successful endoscopic treatment for peptic ulcer bleeding. Can J Gastroenterol 2009; 23(4):287-99.
49. Fornai M., Natale G., Colucci R., et al. Mechanisms of protection by pantoprazole against NSAID-induced gastric mucosal damage. Naunyn Schmiedebergs Arch Pharmacol 2005; 372(1):79-87. Epub 2005 Aug 4.
50. Van Leen M.W., van der Eijk I., Schols J.M. Prevention of NSAID gastropathy in elderly patients. An observational study in general practice and nursing homes. Age Ageing 2007; 36(4):414-8. Epub 2007 May 30.
51. Bianchi Porro G., Lazzaroni M., Imbesi V., et al. Efficacy of pantoprazole in the prevention of peptic ulcers, induced by non-steroidal anti-inflammatory drugs: a prospective, placebo-controlled, double-blind, parallel-group study. Dig Liver Dis 2000; 32(3):201-8.
52. Müller P., Simon B. The action of the proton pump inhibitor pantoprazol against acetylsalicylic acidinduced gastroduodenopathy in comparison to ranitidine. An endoscopic controlled, double blind comparison. Arzneimittelforschung 1998; 48(5):482-5.
53. Stupnicki T., Dietrich K., González-Carro P., et al. Efficacy and tolerability of pantoprazole compared with misoprostol for the prevention of NSAID-related gastrointestinal lesions and symptoms in rheumatic patients. Digestion 2003; 68(4):198-208. Epub 2003 Dec 30.
54. Исаков В.А. Лекарственные взаимодействия ингибиторов протонной помпы: обновленные данные. Best clinical practice. Русское издание, декабрь 2014, 1-12.
55. Wedemeyer R.S., Blume H. Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update. Drug Saf 2014; 37(4):201-11. doi:10.1007/s40264-014-0144-0.
56. Sibbing D., Morath T., Stegherr J., et al. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb Haemost 2009; 101(4):714-9.
57. Fontes-Carvalho R., Albuquerque A., Araújo C., et al. Omeprazole, but not pantoprazole, reduces the antiplatelet effect of clopidogrel: a randomized clinical crossover trial in patients after myocardial infarction evaluating the clopidogrel-PPIs drug interaction. Eur J Gastroenterol Hepatol. 2011; 23(5):396-404.
58. Angiolillo D., Gibson C., Cheng S., et al. Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies. Clin Pharmacol Ther 2011; 89(1):65-74.
59. Cuisset T., Frere C., Quilici J., et al. Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose the PACA (Proton Pump Inhibitors And Clopidogrel Association) prospective randomized study. J Am Coll Cardiol 2009; 54(13):1149-53.
60. Santucci R., Levêque D., Kemmel V., et al. Severe intoxication with methotrexate possibly associated with concomitant use of proton pump inhibitors. Anticancer Res2010;30(3):963-5.
61. Suzuki K., Doki K., Homma M., et al. Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy. Br J Clin Pharmacol 2009; 67(1):44-9.
62. Bezabeh S., Mackey A., Kluetz P., et al. Accumulating evidence for a drug-drug interaction between methotrexate and proton pump inhibitors. Oncologist 2012; 17(4):550-4.
63. Neubauer H., Engelhardt A., Krüger J., et al. Pantoprazole does not influence the antiplatelet effect of clopidogrel a whole blood aggregometry study after coronary stenting. J Cardiovasc Pharmacol 2010; 56(1):91-7. doi:10.1097/FJC.0b013e3181e19739.
64. Kasprzak M., Koziński M., Bielis L., et al. Pantoprazole may enhance antiplatelet effect of enteric-coated aspirin in patients with acute coronary syndrome. Cardiol J 2009; 16(6):535-44.
65. Adkison K.K., Vaidya S.S., Lee D.Y., et al. Oral sulfasalazine as a clinical BCRP probe substrate: pharmacokinetic effects of genetic variation (C421A) and pantoprazole coadministration. J Pharm Sci 2010; 99(2):1046-62. doi:10.1002/jps.21860.
Review
For citations:
Karateyev A.Ye. Modern approaches of effective prevention of NSAIDs-gastropathy. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2015;25(6):92-102. (In Russ.)
Views:
125
Email this article 
